Co-Diagnostics submits FDA 510(k) for Co-Dx PCR Flu A/B & RSV point-of-care test

Reuters2026/08/18 13:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Co-Diagnostics submitted a 510(k) premarket notification to the FDA for its Co-Dx PCR Flu A/B RSV upper-respiratory multiplex test.
Filing covers use on the Co-Dx PCR Pro instrument, part of its point-of-care PCR platform targeted for a potential US launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608180930PR_NEWS_USPR_____LA28476) on August 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Co-Diagnostics submits FDA 510(k) for Co-Dx PCR Flu A/B & RSV point-of-care test

You may also like

Crypto prices